In addition to semaglutide, GLP-1 drugs that have been marketed globally include: tirzepatide, liraglutide, benaglutide, exenatide, lixisenatide, albiglutide, dulaglutide, and Losenatide. Peptides etc. Some are short-acting (such as an injection every day), some are long-acting (such as an injection every week), and some can be injected and taken orally at the same time.
However, currently only four drugs, Tirzepatide, liraglutide, and benaglutide, are approved for weight loss. Several others are only approved for the treatment of type 2 diabetes, and their indications for weight loss are still in the experimental stage. In addition, a number of GLP-1 innovative drugs that have not yet been launched are also undergoing clinical trials.
In fact, with the launch of the oral version of semaglutide, GLP-1 drugs now have oral dosage forms. Compared with injections, oral dosage forms have the advantages of stable hypoglycemic and weight loss effects, as well as being convenient to take and not affected by eating.
A 47-year-old woman tried a weight-loss drug with a similar mechanism to Semaglutide in a clinical trial. She only needed one injection per week and successfully lost nearly 60 kilograms of weight in a year and a half.
In 2020, she participated in a clinical trial of a glucose-dependent insulinotropic peptide (GIP) and GLP-1 receptor dual agonist to treat obesity.
During the 18-month trial, she lost approximately 38.6% of her weight.
However, some experts said that after patients stop taking GLP-1 drugs, they may still gain weight again if they do not pay attention to weight management.
Obesity increases the risk of coronary heart disease, stroke, malignant tumors, respiratory diseases and many other diseases, therefore medical intervention is necessary.
Reference
[1].Heise T, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes [published online ahead of print, 2023 Mar 1]. Diabetes Care, doi:10.2337/dc22-1710
